3551results about "Antiparasitic agents" patented technology

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

The invention belongs to the field of gene engineering, and relates to a gene-deleted recombinant toxoplasma gondii strain vaccine and a construction method thereof, in particular to a gene-deleted recombinant toxoplasma gondii strain, a drug and / or a biological product containing the gene-deleted recombinant toxoplasma gondii strain, a construction method and application of the gene-deleted recombinant toxoplasma gondii strain. The toxoplasmosis vaccine with attenuated activity developed based on the recombinant toxoplasmosis strain is suitable for immunoprophylaxis of toxoplasmosis of various mammals, can block transmission of toxoplasmosis to people and other animals, and is especially suitable for immunoprophylaxis of cat toxoplasmosis infection and / or toxoplasmosis. The vaccine is easy to produce, high in safety, excellent in efficacy, long in immunization duration, capable of distinguishing vaccine immunization from natural infection, free of pollution to animals and the environment, capable of effectively reducing residues of toxoplasma oocysts in the environment and reducing the risk that people are infected with toxoplasmosis, and has huge application potential and important public health significance.

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and / or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

The invention discloses an atorvaquone enteric-coated tablet, the preparation comprises atorvaquone, glyceryl behenate, teloxpol, a filler, an adhesive, a disintegrating agent and an enteric coating, and the particle size D90 of the atorvaquone is 30-50 [mu] m. The atorvaquone enteric-coated tablet disclosed by the invention is stable and continuous in release and high in bioavailability, can be positioned and released in intestinal tracts and reduce liver circulation, so that the occurrence of phenomena such as liver injury is reduced, the phenomena such as sticking and cracking are avoided in a tabletting process, the quality is qualified and stable, and the dissolution performance and the stability of the atorvaquone enteric-coated tablet are also ensured.

Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The invention discloses a fluralamide moxidectin drop and a preparation method thereof, and relates to the technical field of veterinary drugs. The drop is prepared from the following components in parts by weight: 26 to 26.5 parts of fluralan, 1.32 parts of moxidectin, 0.10 part of butylated hydroxytoluene, 29.5 to 30.5 parts of dimethylacetamide, 19.5 to 20 parts of tetrahydrofuran polyethylene glycol ether, 13 to 13.5 parts of diethyl toluamide, 8.5 to 9.3 parts of acetone and 1.0 to 1.5 parts of ethanol. The invention has the effects of improving the stability, permeability and lasting effect of the medicine.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and / or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

The invention discloses a toxoplasma gondii attenuated strain as well as a construction method and application thereof. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 disclosed by the invention is obtained by knocking out MIC1 and MIC3 genes from a TIR1 strain by utilizing a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 can effectively enhance macrophage functions including phagocytic ability, proinflammatory factor secretion and the like, and provides theoretical basis and technical support for clarification of an immunoregulation network of toxoplasma gondii-host interaction and development of vaccine design based on attenuated strains.

The invention relates to the field of veterinary drugs, in particular to a furalan chewable tablet and a preparation method thereof.According to the furalan chewable tablet, a coating agent with xanthan gum, gelatin and other components as main bodies is utilized, the coating performance of the furalan chewable tablet on furalan is improved, and good palatability can be provided on the basis that the whole furalan chewable tablet has good hardness, tablet preparation performance and disintegration performance; the feed is more suitable for animals to eat.

The invention relates to the technical field of medicine formulas, in particular to a fluralamide moxidectin composite drop and a preparation process thereof. The invention relates to a fluralan-moxidectin emulsion which is prepared from the following raw materials in percentage by mass: 26 to 30 percent of fluralan, 1.1 to 1.7 percent of moxidectin, 32 to 36 percent of solvent, 0.1 to 0.3 percent of butylated hydroxytoluene, 10 to 16 percent of polymer carrier and the balance of tetrahydrofuran polyethylene glycol ether. The coexisting drug is stabilized through the core-shell structure polymer carrier, phase separation is prevented, a neutral environment is maintained, long-acting stability is ensured, the transdermal absorption rate is optimized, skin irritation is reduced, and the synergistic drug effect is improved. Meanwhile, the slow release period of the medicine is prolonged, the metabolic interference and accumulated toxicity are reduced, and the dissolution efficiency and the skin mildness are both considered.

The invention belongs to the technical field of gene engineering, and particularly discloses a construction method and application of a toxoplasma gondii gene knockout vaccine strain, a TGGT1202920 gene of toxoplasma gondii is directly knocked out through a gene editing technology to obtain a delta TGGT1202920 strain, and the strain has the characteristics that the strain can be normally cultured in vitro and is almost non-toxic in vivo; after animals are immunized with delta TGGT1202920 strains, good immune protection can be generated, infection of wild type toxoplasma gondii can be resisted, and the strain can be used for preparing toxoplasmosis resistant vaccines to prevent toxoplasma gondii infection.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GABA (gamma-aminobutyric acid) driven by lactobacillus rhamnosus to treatment of cerebral malaria of mice. According to the invention, the obviously enriched lactobacillus muricatum is found, and the lactobacillus muricatum is proved to be capable of generating GABA (gamma-aminobutyric acid). Afterwards, on the mouse cerebral malaria model, under the condition that the lactobacillus rhamnosus and the GABA are independently used or auxiliary dihydroartemisinin is used, the effect of the lactobacillus rhamnosus and the GABA on improving and treating the mouse cerebral malaria is evaluated. Results show that the strain and the metabolite GABA thereof can effectively improve behavioristics of mice and immune pathological injuries of all organs, reduce protozoemia and prolong the lifetime of the mice whether the strain is independently used or combined with dihydroartemisinin, and can effectively treat cerebral malaria of the mice compared with the strain which is independently used with drugs. The invention provides a brand-new solution for treating severe malaria, especially human brain malaria, caused by malignant malaria from the perspective that the probiotics drive metabolites of the probiotics to assist the anti-malarial drug in treating rat brain malaria.

The invention discloses a moxidectin pouring solution and a preparation method thereof, and belongs to the technical field of veterinary drug preparations. Every 500 ml of the moxidectin pouring solution comprises 0.1%-10% of moxidectin, an antioxidant, a penetrating agent, a tackifier, a cosolvent, a coloring agent and the balance of a fat solvent, and preferably, soybean oil is used as the fat solvent. The preparation method comprises the following steps: mixing and dissolving the components according to a specific sequence, filtering and sub-packaging. The moxidectin pouring solution disclosed by the invention has the advantages of low cost, convenience in preparation, good quality stability, no influence on impurity detection and the like, effectively solves a plurality of problems of the moxidectin pouring solution in the prior art, and has a good application prospect.

The invention relates to an anti-cryptosporidium micromolecular lead compound of a target cryptosporidium helicase. Comprising the following steps: S1, detecting enzyme activity parameters of a drug target helicase (CpeIF4A) and an inhibition effect of Roc-A on the drug target helicase: expressing and purifying a CpeIF4A recombinant protein containing an MBP tag; detecting the enzyme activity; detecting the inhibition effect of the Roc-A on the enzyme activity; determining the affinity between the Roc-A and the CpeIF4A through a heat transfer experiment; s2, in-vitro drug effect determination: evaluating the direct killing capability of Roc-A on sporozoites; the inhibition effect of Roc-A on cryptosporidium is determined through an in-vitro cell infection model, an EC50 value is obtained, and the intracellular period of the Roc-A mainly playing the inhibition effect is determined; detecting the toxicity of Roc-A to host cells to obtain a TC5 value), and obtaining an in-vitro insect-resistant selectivity index (SI); and S3, in-vivo drug effect test: establishing a C57BL / 6IFN-gamma gene knockout mouse infection model to evaluate the effectiveness and safety of Roc-A. The invention determines that the Roc-A has the potential of being further developed into the cryptosporidium-resistant drug, and verifies that the targeted eIF4A can resist cryptosporidium infection.

The invention discloses a temperature-sensitive hydrogel based on Chinese prickly ash alkaloid. The temperature-sensitive hydrogel is prepared from poloxamer 407, poloxamer 188 and Chinese prickly ash alkaloid powder. The temperature-sensitive hydrogel based on the pepper alkaloid prepared by the invention has three characteristics of biological adhesion, self-healing property and slow release property, and solves the technical problems that the pepper alkaloid is poor in stability and uncontrollable in drug release.

The invention relates to the technical field of biological pharmacy, in particular to a novel vaccine delivery system. According to the vaccine delivery system, lymph node co-delivery of the antigen and the adjuvant can be achieved, the immunity promoting effect of the adjuvant is effectively enhanced, the specific immune response of the antigen is remarkably improved, and the vaccine delivery system is superior to a clinically common oil type composite adjuvant system. Particularly, the vaccine delivery system shows a remarkable anti-tumor effect in tumor prevention and treatment, and a new thought is provided for development and application of a novel vaccine system.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The invention belongs to the field of meat pigeon breeding, and particularly relates to miRNAs capable of serving as a trichomonad pigeon biomarker and application of the miRNAs. The invention provides application of miRNAs as a trichomonas pigeonae biomarker in preparation of a trichomonas pigeonae diagnostic reagent. According to the invention, high-throughput sequencing and bioinformatics analysis are simultaneously carried out on oral mucosa small RNA and transcriptome of a trichomonad infected positive individual and a healthy individual for the first time, so that an epigenetic molecular mechanism of oral mucosa tissue of a trichomonad infected regulation body is explained by mining a key significant difference miRNA-mRNA network.

The invention discloses application of ursolic acid in resisting fish ichthyophthiriasis. The ursolic acid has a remarkable killing effect on ichthyophthirius multifilis in an in-vitro stage, and the 4-hour half effective insecticidal concentration (4h-EC50) of the ursolic acid on a grazing body is 0.3774 mg / L; and the 22-hour half effective insecticidal concentration (22h-EC 50) on the capsule is 4.931 mg / L. An acute toxicity test shows that the 96-hour median lethal concentration (96h-LC50) of ursolic acid to goldfish is 9.358 mg / L, the therapeutic index (TI = 96h-LC50 / 4h-EC50) is up to 24.8, and the safety of ursolic acid is remarkably superior to that of a traditional medicine. Ursolic acid used in the invention is a plant-derived active component, has the characteristics of high environmental compatibility and low biological accumulation, meets the development requirements of green fishery, and has an industrialization basis for being developed into eco-friendly aquatic products.

The invention relates to the technical field of microorganisms, in particular to lactobacillus rhamnosus HZBX-05 and application thereof.The lactobacillus rhamnosus HZBX-05 is sent to the China General Microbiological Culture Collection Center on July 27th, 2023 to be preserved in the China General Microbiological Culture Collection Center, the preservation number of the lactobacillus rhamnosus HZBX-05 is CGMCC NO.987, and the preservation number of the lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28035, and the address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing; the separated Lactobacillus rhamnosus HZBX-05 is continuously treated for 7 hours in a simulated gastric acid cholate environment, and the result shows that the HZBX-05 still has high survival rate, has the capability of being highly adsorbed to intestinal cells Caco-2 cells, has the capability of inhibiting various pathogenic bacteria, has immunoregulation and anti-inflammation effects, has the effect of resisting helicobacter pylori, and can be used for preparing an anti-inflammatory drug. The symptoms of female vaginitis can be improved.

Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.